Hangzhou Tigermed Consulting Co., Ltd

Equities

300347

CNE100001KV8

Biotechnology & Medical Research

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
53.01 ^CNY	+0.78%		+0.47%	-3.57%

02:18pm	Hangzhou Tigermed Consulting’s Profit Down 59% in Q1	MT
10:53am	Hangzhou Tigermed Consulting Co., Ltd Reports Earnings Results for the First Quarter Ended March 30, 2024	CI

Shanghai OMNI Pharmaceutical Technology Co., Ltd. announced that it has received $31.4 million in funding from Hangzhou Tigermed Consulting Co., Ltd, Shanghai Healthcare Capital Partnership (Limited Partnership), Yuanlai Capital, Bank of China Group Investment Limited, Yuanxin Private Fund Management Co., Ltd.

December 26, 2021

Shanghai OMNI Pharmaceutical Technology Co., Ltd. announced that it has received $31,400,000 in funding led by Shanghai Healthcare Capital Partnership (Limited Partnership) on December 27, 2021. The transaction included participation from Hangzhou Tigermed Consulting Co., Ltd, Yuanlai Capital, Bank of China Group Investment Limited, and Yuanxin (Zhuhai) Private Fund Management Co., Ltd.

Latest news about Hangzhou Tigermed Consulting Co., Ltd

Hangzhou Tigermed Consulting’s Profit Down 59% in Q1	08:18am	MT
Hangzhou Tigermed Consulting Co., Ltd Reports Earnings Results for the First Quarter Ended March 30, 2024	04:53am	CI
Tigermed Consulting's Profit, Revenue Climb in 2023	Mar. 29	MT
Hangzhou Tigermed Consulting Co., Ltd Announces Final Dividend for the Year Ended December 31, 2023, Payable on 31 July 2024	Mar. 28	CI
Hangzhou Tigermed Consulting Co., Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Hangzhou Tigermed Consulting Co., Ltd Announces Executive Changes	Mar. 21	CI
China Healthcare Stocks Rally on Hopes for Government Support	Mar. 14	DJ
China stocks steady, helped by biotech rally; Wuxi Apptec drags Hong Kong shares	Mar. 14	RE
Nomura Downgrades Hangzhou Tigermed Consulting to Neutral From Buy, Adjusts Price Target to 49.61 Yuan From 75.72 Yuan	Mar. 05	MT
Nomura Downgrades Tigermed to Neutral From Buy, Adjusts Price Target to HK$32.69 From HK$57.77	Mar. 05	MT
Hangzhou Tigermed Consulting Plans Up to 1 Billion Yuan Share Repurchase; Shares Jump 4%	Feb. 07	MT
Hangzhou Tigermed Consulting Co., Ltd announces an Equity Buyback for CNY 1,000 million worth of its shares.	Feb. 06	CI
Hangzhou Tigermed Consulting Co., Ltd authorizes a Buyback Plan.	Feb. 05	CI
Nomura Adjusts Hangzhou Tigermed Consulting' Price Target to 75.72 Yuan from 83.50 Yuan, Keeps at Buy	23-10-30	MT
Nomura Adjusts Hangzhou Tigermed Consulting' Price Target to HK$57.77 from HK$64.46, Keeps at Buy	23-10-30	MT
Hangzhou Tigermed Consulting's Profit Up 19% in Q3	23-10-27	MT
Hangzhou Tigermed Consulting Co., Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-27	CI
Tigermed Consulting's Profit Jumps 16.5% in H1	23-08-28	MT
Hangzhou Tigermed Consulting Co., Ltd Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-25	CI
Tigermed Officially Opens International Headquarters in Hong Kong	23-08-16	CI
Bioclub announced that it has received funding from Hangzhou Tigermed Consulting Co., Ltd	23-08-06	CI
Nomura Adjusts Tigermed to Buy From Neutral, Adjusts Price Target to 83.50 Yuan From 91.67 Yuan	23-07-24	MT
Nomura Upgrades Tigermed to Buy From Neutral, Adjusts Price Target to HK$64.46 From HK$79.47	23-07-24	MT
Hangzhou Tigermed Consulting Co., Ltd. Announces Final Profit Distribution Plan Implementation (A Shares) for 2022, Payable on 07 July 2023	23-07-04	CI
Hangzhou Tigermed Consulting Co. Ltd. Proposes Ordinary Final Dividend for the Year Ended December 31, 2022, Payable on 07 July 2023	23-06-26	CI

Chart Hangzhou Tigermed Consulting Co., Ltd

Duration

Period

Chart Hangzhou Tigermed Consulting Co., Ltd

More charts

Company Profile

Hangzhou Tigermed Consulting Co, Ltd. specialises in providing professional services to pharmaceutical and biotech companies. The group supports its clients in all processes of clinical development and product commercialization. Net sales break down by activity as follows: - provision of clinical trial services and related technological services (51.8%); - provision of clinical research consulting services (48.2%). China accounts for 46% of sales.

Sector

Biotechnology & Medical Research

Calendar

2024-04-24 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Hangzhou Tigermed Consulting Co., Ltd

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

53.01 CNY

Average target price

61.88 CNY

Spread / Average Target

+16.74%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
HANGZHOU TIGERMED CONSULTING CO., LTD	-3.57%	5.88B
IQVIA HOLDINGS INC.	+1.12%	43.84B
MODERNA, INC.	+6.77%	41.68B
LONZA GROUP AG	+45.26%	41.25B
CELLTRION, INC.	-11.96%	27.04B
ICON PUBLIC LIMITED COMPANY	+6.01%	25.53B
ALNYLAM PHARMACEUTICALS, INC.	-24.92%	18.18B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.63%	12.29B
MEDPACE HOLDINGS, INC.	+27.16%	12.29B
UNITED THERAPEUTICS CORPORATION	+7.30%	11.15B

Other Biotechnology & Medical Research